Published DateClear

Start Date

End Date

Category

• Business1
• Legal1
• Products1

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.46
• American Optometric Association37
• Harrow30
• Glaukos27
• Topcon Healthcare25
• Regeneron24
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• AMD2
• DME2
• Eylea2
• Biosimilar2
• Diabetic Retinopathy2
• Injections2
• Products2
• Retina2
• Retinal Vein Occlusion (rvo)2
• Wet Amd2

• Organizations: Samsung Bioepis ✕

Clear all

Legal

Samsung Biopeis and Regeneron settle EYLEA biosimilar US patent dispute

Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.

Business

Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio

Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.